344 related articles for article (PubMed ID: 17209764)
1. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
3. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
4. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
[TBL] [Abstract][Full Text] [Related]
5. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A
J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
8. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
[TBL] [Abstract][Full Text] [Related]
9. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
10. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Khanlou H; Yeh V; Guyer B; Farthing C
AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
[TBL] [Abstract][Full Text] [Related]
11. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
13. [Tenofovir DF in rescue regimens].
López Bernaldo de Quirós JC
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
[TBL] [Abstract][Full Text] [Related]
14. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
15. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
McColl DJ; Margot NA; Wulfsohn M; Coakley DF; Cheng AK; Miller MD
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1340-50. PubMed ID: 15483463
[TBL] [Abstract][Full Text] [Related]
16. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
17. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
[TBL] [Abstract][Full Text] [Related]
18. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
[TBL] [Abstract][Full Text] [Related]
19. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Wirden M; Marcelin AG; Simon A; Kirstetter M; Tubiana R; Valantin MA; Paris L; Bonmarchand M; Conan F; Kalkias L; Katlama C; Calvez V
J Med Virol; 2005 Jul; 76(3):297-301. PubMed ID: 15902696
[TBL] [Abstract][Full Text] [Related]
20. Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy.
Chaplin B; Imade G; Onwuamah C; Odaibo G; Audu R; Okpokwu J; Olaleye D; Meloni S; Rawizza H; Muazu M; Musa AZ; Samuel J; Agbaji O; Ezechi O; Idigbe E; Kanki PJ
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):228-233. PubMed ID: 29084434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
